Reports Q1 revenue $3.56M, consensus $4.49M. “During the first quarter of 2026, we remained focused on advancing AMT-130 to patients globally as rapidly as possible while executing across our broader pipeline,” said Matthew Kapusta, chief executive officer at uniQure (QURE). “We believe our data continue to support the potential for AMT-130 to fundamentally change the treatment landscape for Huntington’s disease, and we look forward to continued engagement with the FDA. In parallel, following a constructive interaction with the MHRA, we are preparing to submit an MAA in the third quarter and evaluating additional international opportunities.”
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QURE:
- uniQure price target raised to $37 from $31 at Chardan
- uniQure advances AMT-130 toward UK marketing approval
- Which 3 Stocks Have the Most Upside in U.S. Chess Champion Hikaru’s Portfolio?
- uniQure price target raised to $10 from $9 at Goldman Sachs
- uniQure call volume above normal and directionally bullish